England agrees to pay for Vertex’s sickle cell disease gene therapy
Vertex Pharmaceuticals and the National Health Service in England have reached a payment deal making the gene-edited therapy Casgevy available to certain people with sickle cell disease. The NHS said...
View ArticleGenentech joins suits against STD clinics over 340B discounts
Genentech is the latest drugmaker to sue the federal government over STD clinics it says are wrongfully receiving discounts through the federal 340B program. The company claimed Friday that several...
View ArticleAbbVie executives bask in Skyrizi, Rinvoq successes as the drugs take up...
The reports of AbbVie’s demise have been greatly exaggerated. Gone are the worries of Humira competition and its monumental patent cliff. The “lack of a shiny object” in the pipeline is a ...
View ArticleRFK Jr. continues to evade questions on vaccines and autism
Robert F. Kennedy Jr.’s chances of becoming HHS chief likely hinge on one of his more controversial stances: that vaccines contribute to the development of autism. And in written responses to ...
View ArticleRFK Jr. hearings leave key GOP senator “struggling”; Drugmakers report Q4...
Welcome back to Endpoints Weekly, thanks for starting your weekend with us. This week’s news was dominated by Robert F. Kennedy Jr.’s confirmation hearings to be HHS Secretary, as Kennedy faced two...
View ArticlePfizer says new colorectal cancer data could support full approval of Braftovi
Pfizer’s Braftovi combo regimen helped prolong the lives of certain patients with previously untreated colorectal cancer, and the company hopes the results will support Braftovi’s conversion from an...
View ArticleJ&J’s Rybrevant gets CHMP backing weeks after FDA rejection
Johnson & Johnson’s subcutaneous form of Rybrevant has been recommended for approval by the European Medicines Agency’s human medicines committee (CHMP), less than two months after it was rejected...
View ArticleDrug prices likely to soar due to Trump tariffs, pharma bodies warn
Pharmaceutical industry groups caution that President Donald Trump’s tariffs on China, Mexico and Canada will likely exacerbate existing drug shortages in the US, raise drug prices and put generic...
View ArticleAustralian biotech AdvanCell nabs $112M Series C for radiopharmaceuticals
Radiopharmaceuticals biotech AdvanCell has pulled together a $112 million Series C about two years after its much smaller Series B of $12 million. Since that financing took place in 2022, the...
View ArticleAlgiax declares Phase 2 win for non-opioid drug for neuropathic pain
Algiax Pharmaceuticals’ non-opioid candidate has achieved “clinically meaningful” pain reduction in a mid-stage trial of people with peripheral post-surgical neuropathic pain, marking another success...
View ArticleTectonic to raise $185M; Acelyrin drops rights to Affibody drug
Plus, news about Immunome, 89bio and Valneva: Tectonic’s $185M private placement: After a hectic week of stock swings, Tectonic Therapeutic disclosed plans for a large private placement. The...
View ArticleSionna seeks $135M IPO to fuel tests of cystic fibrosis drug candidates
Cystic fibrosis drug developer Sionna Therapeutics hopes to join the IPO wave started by Metsera and Maze Therapeutics last week. Sionna, which snagged some of its programs from AbbVie last year, hopes...
View ArticleDrugmakers seize on biomarkers to test the FDA's rare disease shift
For the first time, the FDA will consider whether to approve a trio of drugs for tiny patient populations based on trials that are using new biological signals as outcomes, rather than a placebo...
View ArticleGH Research reports Phase 2b triumph for short-acting psychedelic drug in...
GH Research has shared compelling data in people with a traditionally challenging form of depression who were dosed with its psychedelic candidate, despite the drug being under a clinical hold in the...
View ArticleThermo Fisher to lay off 300 workers at two viral vector factories
Thermo Fisher Scientific is cutting 300 employees across two viral vector manufacturing facilities in Massachusetts, marking the second round of layoffs at those factories in the past few months. The...
View ArticleSenate Democrats criticize RFK Jr.'s divestment plans ahead of Tuesday vote
Democrats in the Senate Finance Committee are calling Robert F. Kennedy Jr.'s new divestment plans to his son "plainly inadequate" ahead of a Tuesday vote on whether to advance his nomination to lead...
View ArticleCharles River to shut down North Carolina pathology facility
Charles River Laboratories is permanently closing its pathology facility in Durham, NC, after determining it is no longer “a strategic fit,” a company spokesperson told Endpoints News in an email....
View ArticleBiogen's research chief talks China, neuropsychiatry and pipeline plan
Fresh off a reorganization, Biogen’s research leader Jane Grogan says the biotech has to “look outside the walls of the company” to avoid being left behind. In her first interview since then, she told ...
View ArticleNoom cuts coaches, staff as fewer sign up
Noom has laid off employees in coaching and customer service after its bet on prescribing GLP-1 drugs wasn't enough to offset losses from its original program, Endpoints News has learned. The job cuts...
View ArticleUS biosimilar 'void' spells trouble as biologic patent expirations loom,...
While 118 biologics are expected to lose patent protection in the US over the next decade, that $234 billion opportunity for biosimilar developers may not materialize because of several challenges,...
View Article